{"id":"NCT03338023","sponsor":"Eli Lilly and Company","briefTitle":"A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus","officialTitle":"A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-23","primaryCompletion":"2020-03-05","completion":"2020-03-05","firstPosted":"2017-11-09","resultsPosted":"2021-03-29","lastUpdate":"2021-03-29"},"enrollment":272,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes"],"interventions":[{"type":"DRUG","name":"LY2963016","otherNames":[]},{"type":"DRUG","name":"Lantus®","otherNames":[]},{"type":"DRUG","name":"Insulin Lispro","otherNames":[]}],"arms":[{"label":"LY2963016 + Insulin Lispro","type":"EXPERIMENTAL"},{"label":"Lantus® + Insulin Lispro","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in combination with mealtime insulin lispro in adult Chinese participants with Type 1 Diabetes Mellitus (T1DM).","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®)","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"LY2963016 + Insulin Lispro","deltaMin":-0.2,"sd":0.071},{"arm":"Lantus® + Insulin Lispro","deltaMin":-0.08,"sd":0.071}],"pValues":[{"comp":"OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":20,"countries":["China"]},"refs":{"pmids":["35471721"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":137},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Injection site pain","Diarrhoea","Toothache"]}}